Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 1
1986 1
1990 1
1991 1
1993 2
1994 2
1995 3
1996 1
1998 1
1999 1
2001 1
2002 1
2004 1
2005 1
2006 6
2007 16
2008 24
2009 27
2010 24
2011 23
2012 21
2013 20
2014 26
2015 21
2016 13
2017 23
2018 22
2019 20
2020 20
2021 8
2022 12
2023 10
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Results by year

Filters applied: . Clear all
Page 1
Iron chelation therapy.
Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Bova C, Filippelli G, Capodanno I, Neri A, Morabito F, Gentile M, Vigna E. Bruzzese A, et al. Eur J Haematol. 2023 May;110(5):490-497. doi: 10.1111/ejh.13935. Epub 2023 Feb 8. Eur J Haematol. 2023. PMID: 36708354 Review.
Identifying iron using noninvasive techniques allowed a better understanding of the rate of iron overload in different organs, with a low risk for the patient. Estimating serum ferritin (mg/L) is the easiest and, consequently, the most employed diagnostic tool for a …
Identifying iron using noninvasive techniques allowed a better understanding of the rate of iron overload in different organs, …
Myelodysplastic Syndromes and Iron Chelation Therapy.
Angelucci E, Urru SA, Pilo F, Piperno A. Angelucci E, et al. Mediterr J Hematol Infect Dis. 2017 Mar 1;9(1):e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28293409 Free PMC article. Review.
Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the mye
Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chel
[Transfusions and iron chelation in myelodysplastic syndromes].
Pascal L. Pascal L. Bull Cancer. 2023 Nov;110(11):1176-1182. doi: 10.1016/j.bulcan.2023.06.004. Epub 2023 Aug 4. Bull Cancer. 2023. PMID: 37543453 Free article. Review. French.
Iron overload (IO) is probably as toxic in elderly patients with low-risk myelodysplastic syndromes (MDS) as in young thalassemic patients. ...In recent years, registry studies have shown a survival benefit of Iron Chelation Therapy (ICT)
Iron overload (IO) is probably as toxic in elderly patients with low-risk myelodysplastic syndromes (MDS) as in young t
Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment.
Nachtkamp K, Kobbe G, Gattermann N, Germing U. Nachtkamp K, et al. Dtsch Arztebl Int. 2023 Mar 24;120(12):203-210. doi: 10.3238/arztebl.m2023.0005. Dtsch Arztebl Int. 2023. PMID: 36718105 Free PMC article. Review.
BACKGROUND: Myelodysplastic syndromes (MDS) are malignant diseases arising from hematopoietic stem cells. ...The median survival time is three years. Myelodysplastic syndromes take a variable course; one-quarter of patients go on to develop acute leuke …
BACKGROUND: Myelodysplastic syndromes (MDS) are malignant diseases arising from hematopoietic stem cells. ...The median surviv …
Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S, Santini V, Musallam K, Taher A. Temraz S, et al. Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. Crit Rev Oncol Hematol. 2014. PMID: 24529413 Review.
Under these circumstances, iron chelation therapy could play an integral role in the management of these patients. ...It also discusses management options in relation to chelation therapy used in MDS patients and the impact it has on survival, h …
Under these circumstances, iron chelation therapy could play an integral role in the management of these patients. ...I …
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Bewersdorf JP, Zeidan AM. Bewersdorf JP, et al. Cancers (Basel). 2021 Mar 31;13(7):1610. doi: 10.3390/cancers13071610. Cancers (Basel). 2021. PMID: 33807279 Free PMC article. Review.
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are two distinct blood cancers with a variable clinical symptom burden and risk of progression to acute myeloid leukemia. ...While supportive care with red blood cell transfusions, erythropoiesis-sti
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are two distinct blood cancers with a variable clinical sym
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA, Gattermann N. Leitch HA, et al. Crit Rev Oncol Hematol. 2019 Sep;141:54-72. doi: 10.1016/j.critrevonc.2019.06.002. Epub 2019 Jun 10. Crit Rev Oncol Hematol. 2019. PMID: 31228649 Review.
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenias and progression to acute myeloid leukemia (AML). ...RBC transfusion dependence and iron overload portend inferior overall survival. Some studies indicate
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenias and progression to ac
New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A, Bravo GM. Bazinet A, et al. Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23. Curr Treat Options Oncol. 2022. PMID: 35320468 Review.
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the International Prognostic Scoring System (IPSS) or its revised version (IPSS-R). ...Given the need for supportive care with red blood cell (RBC) transf …
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the Internatio …
Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.
Liu H, Yang N, Meng S, Zhang Y, Zhang H, Zhang W. Liu H, et al. Clin Exp Med. 2020 Feb;20(1):1-9. doi: 10.1007/s10238-019-00592-5. Epub 2019 Nov 11. Clin Exp Med. 2020. PMID: 31712933
Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still
Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfus
Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms-Real-World Data from the German Noninterventional Study EXCALIBUR.
Schulz F, Hauch U, Ketzler-Henkel S, von der Heyde E, Koenigsmann M, Lauseker M, Schulte N, Germing U. Schulz F, et al. J Clin Med. 2023 Oct 17;12(20):6569. doi: 10.3390/jcm12206569. J Clin Med. 2023. PMID: 37892707 Free PMC article.
Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow failure often resulting in anemia. For those patients, transfusion of red blood cell (RBC) units is essential but results in iron overlo
Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow fai
312 results